Cargando…

Longitudinal analysis of contrast acuity in Friedreich ataxia

OBJECTIVE: To determine the natural history of contrast acuity in Friedreich ataxia. METHODS: In the Friedreich Ataxia–Clinical Outcome Measures Study, participants (n = 764) underwent binocular high- and low-contrast visual acuity testing at annual study visits. Mixed-effects linear regression was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamedani, Ali G., Hauser, Lauren A., Perlman, Susan, Mathews, Katherine, Wilmot, George R., Zesiewicz, Theresa, Subramony, S.H., Ashizawa, Tetsuo, Delatycki, Martin B., Brocht, Alicia, Lynch, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066362/ https://www.ncbi.nlm.nih.gov/pubmed/30065952 http://dx.doi.org/10.1212/NXG.0000000000000250

Ejemplares similares

Progression of Friedreich ataxia: quantitative characterization over 5 years
por: Patel, Maya, et al.
Publicado: (2016)

Psychometric properties of the Friedreich Ataxia Rating Scale
por: Rummey, Christian, et al.
Publicado: (2019)

Impact of diabetes in the Friedreich ataxia clinical outcome measures study
por: McCormick, Ashley, et al.
Publicado: (2017)

Frataxin levels in peripheral tissue in Friedreich ataxia
por: Lazaropoulos, Michael, et al.
Publicado: (2015)

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
por: Lynch, David R., et al.
Publicado: (2020)

Natural History of Friedreich Ataxia: Heterogeneity of Neurologic Progression and Consequences for Clinical Trial Design
por: Rummey, Christian, et al.
Publicado: (2022)

Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort
por: Rummey, Christian, et al.
Publicado: (2021)

A non-synonymous single nucleotide polymorphism in SIRT6 predicts neurological severity in Friedreich ataxia
por: Rodden, Layne N., et al.
Publicado: (2022)

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
por: Lynch, David R., et al.
Publicado: (2018)

Body Mass Index and Height in the Friedreich Ataxia Clinical Outcome Measures Study
por: Patel, Maya, et al.
Publicado: (2021)

Randomized, double‐blind, placebo‐controlled study of interferon‐γ 1b in Friedreich Ataxia
por: Lynch, David R., et al.
Publicado: (2019)

Test–retest reliability of the Friedreich’s ataxia rating scale
por: Rummey, Christian, et al.
Publicado: (2020)

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022)

Consensus clinical management guidelines for Friedreich ataxia
por: Corben, Louise A, et al.
Publicado: (2014)

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias
por: Gan, Shi-Rui, et al.
Publicado: (2017)

Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
por: Ghanekar, Shaila D, et al.
Publicado: (2019)

Auditory neuropathy in mice and humans with Friedreich ataxia
por: Rance, Gary, et al.
Publicado: (2023)

Somatic instability of the expanded GAA repeats in Friedreich’s ataxia
por: Long, Ashlee, et al.
Publicado: (2017)

Comprehensive Phenotype of the p.Arg420his Allelic Form of Spinocerebellar Ataxia Type 13
por: Subramony, SH, et al.
Publicado: (2013)

Vascular Risk Factors and Clinical Progression in Spinocerebellar Ataxias
por: Lo, Raymond Y., et al.
Publicado: (2015)

Predictors of loss of ambulation in Friedreich's ataxia
por: Rummey, Christian, et al.
Publicado: (2020)

Frataxin deficiency alters gene expression in Friedreich ataxia derived IPSC‐neurons and cardiomyocytes
por: Angulo, Mariana B., et al.
Publicado: (2022)

Friedreich's Ataxia
por: Anderson, J. Wallace
Publicado: (1893)

Friedreich Ataxia: Multidisciplinary Clinical Care
por: Lynch, David R, et al.
Publicado: (2021)

Characterization of the retinal pigment epithelium in Friedreich ataxia
por: Crombie, Duncan E., et al.
Publicado: (2015)

The current state of biomarker research for Friedreich’s ataxia: a report from the 2018 FARA biomarker meeting
por: Blair, Ian A, et al.
Publicado: (2019)

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study
por: Ashizawa, Tetsuo, et al.
Publicado: (2013)

The Pathology of Friedreich's Ataxia
por: Rainy, Harry
Publicado: (1905)

Neuroinflammation in Friedreich’s Ataxia
por: Apolloni, Savina, et al.
Publicado: (2022)

Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia
por: Rodden, Layne N, et al.
Publicado: (2021)

Central Nervous System Therapeutic Targets in Friedreich Ataxia
por: Harding, Ian H., et al.
Publicado: (2020)

Clinical Evidence for Variegated Silencing in Patients With Friedreich Ataxia
por: Rodden, Layne N., et al.
Publicado: (2022)

The Pathogenesis of Cardiomyopathy in Friedreich Ataxia
por: Koeppen, Arnulf H., et al.
Publicado: (2015)

Differences in the determinants of right ventricular and regional left ventricular long-axis dysfunction in Friedreich ataxia
por: Peverill, Roger E., et al.
Publicado: (2018)

SARS-CoV-2 in patients with Friedreich ataxia
por: Shen, Megan M., et al.
Publicado: (2022)

Is Friedreich ataxia an epigenetic disorder?
por: Kumari, Daman, et al.
Publicado: (2012)

Depressive symptoms in Friedreich ataxia
por: Nieto, Antonieta, et al.
Publicado: (2018)

Heart disease in Friedreich’s ataxia
por: Hanson, Emily, et al.
Publicado: (2019)

Drug Repositioning in Friedreich Ataxia
por: Rufini, Alessandra, et al.
Publicado: (2022)

Two Cases of Friedreich’s Ataxia
por: Stephenson, F. H.
Publicado: (1897)

Cannot write session to /tmp/vufind_sessions/sess_v8bn5foc8pibsttgsrmguqlv9j